Bioservo finalizes the clinical study iHand

Together with research institute Roessingh Research and Development in the Netherlands, Bioservo has finalized the clinical study iHand, investigating the therapeutic effect of using Carbonhand, "Six weeks use of a wearable soft-robotic glove during ADL". 63 participants with impaired hand function, have used Carbonhand as an assistive aid during activities of daily living for six weeks and preliminary data show significant improvement in both grip strength and hand functionality.¹

The average time from impairment to inclusion in the study was almost 10 years for the study participants, and measurements were done before inclusion in order to make sure that the participants were in a stable phase so that no spontaneous improvement or decrease would occur during the intervention period. Interim results from the first 49 participants, was presented during IFSSH in London in June, and shows significant improvements in both grip strength (+27%) and in hand function (+12%) according to Jebsen Taylor Hand Function Test (JTHFT)¹. The last participant has now finalized its participation in the study and the study are thereby finalized. Next step is to validate and analyse the data before it can be submitted to a journal for publication of the final results.

"Based on the interim results presented earlier this year, we are looking forward to be able to share the final results from the study." Says Prof. J.S. (Hans) Rietman MD, PhD. He is physiatrist and professor in Rehabilitation Medicine & Technology at the University of Twente and continues "Increasing the grip strength and hand function already after six weeks use, and with a sustainable therapeutic effect is of huge importance for these users and shows that use of Carbonhand for a relatively short time can already result in improved hand function. This is very promising for future healthcare scenarios."

¹ Kottink AIR, Nikamp CDM, Buurke JH, Bos F, van der Sluis CK, van den Broek M, Onneweer B, Stolwijk-Swüste JM, Brink SM, Rietman JS, Prange-Lasonder GB. Six weeks use of a wearable soft-robotic glove during ADL: preliminary results of ongoing clinical study. International Federation of Societies for Surgery of the Hand and International Federation of Societies for Hand Therapy, IFSSH & IFSHT, London, 6-10 juni 2022.

The clinical trial has been conducted within the framework of the iHand project. The project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 801945.

For more information, please contact:
Petter Bäckgren, CEO, Bioservo Technologies AB
Telefon: [phone]
[e-mail]

Niklas Lagström, Global Brand Manager - Life Science, Bioservo Technologies AB
Telefon: [phone]
[e-mail]

About Bioservo Technologies

Bioservo Technologies AB (publ) is a world leading company in wearable muscle strengthening systems for people in need of extra strength and endurance. All our innovative products and systems are designed to keep people strong, healthy, and efficient. The company has a unique global position within soft exoskeleton technology for the hand, both for industrial applications to improve the health for workers and to improve quality of life for people with reduced muscle strength. Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska University Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Stockholm.

FNCA Sweden AB is the company's Certified Adviser on Nasdaq First North

For more information, please visit www.bioservo.com

https://news.cision.com/bioservo-technologies-ab--publ-/r/bioservo-finalizes-the-clinical-study-ihand,c3640748

(c) 2022 Cision. All rights reserved., source Press Releases - English